Jyong Biotech shares surge 14.71% intraday after showcasing positive Phase III BOTRESO and Phase II MCS-8 clinical data at Asia Urology Congress.

Jyong Biotech (NASDAQ:MENS) surged 14.71% intraday following the presentation of clinical data for its Phase III botanically derived drug BOTRESO and Phase II candidate MCS-8 at the 22nd Urological Association of Asia Congress on August 22, 2025. The company also announced the submission of a New Drug Application (NDA) for Botreso in the U.S., marking a regulatory milestone. These developments underscored progress in commercializing Botreso for benign prostatic hyperplasia and expanding MCS-8’s pipeline for prostate cancer prevention, aligning with the stock’s sharp rise as investors reacted positively to clinical validation and regulatory advancements.